A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase

Journal of Clinical Investigation

Volumn 119, Issue 7, 2009, Pages 1964-1973

  Patel, Naina ^a   Krishnan, Shekhar ^a   Offman, Marc N ^b   Krol, Marcin ^b   Moss, Catherine X ^c,g   Leighton, Carly ^a,h   Van Delft, Frederik W ^a,i   Holland, Mark ^a   Liu, JiZhong ^a   Alexander, Seema ^a   Dempsey, Clare ^a   Ariffin, Hany ^d   Essink, Monika ^e   Eden, Tim O B ^f   Watts, Colin ^c   Bates, Paul A ^b   Saha, Vaskar ^a,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e MEDAC GMBH   (Germany)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINYL ENDOPEPTIDASE, LYSOSOMAL; CATHEPSIN B; CYSTEINE PROTEINASE;

CELL LINE; ENZYMOLOGY; HUMAN; LYMPHOCYTE; LYSOSOME; METABOLISM; PHYSIOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CATHEPSIN B; CELL LINE; CYSTEINE ENDOPEPTIDASES; HUMANS; LYMPHOCYTES; LYSOSOMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 68849086963     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/jci37977     Document Type: Article

References (44)

1. Roy, A., et al. 2005. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br. J. Haematol. 129:35-44.
2. Yang, L., et al. 2008. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J. Clin. Oncol. 26:1932-1939.
3. Abshire, T.C., Pollock, B.H., Billett, A.L., Bradley, P., and Buchanan, G.R. 2000. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 96:1709-1715.
4. Pession, A., et al. 2005. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23:7161-7167.
5. Moghrabi, A., et al. 2007. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 109:896-904.
6. Asselin, B.L., et al. 1999. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 21:6-12.
7. Appel, I.M., et al. 2008. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 22:1665-1679.
8. Holleman, A., den Boer, M.L., Kazemier, K.M., Janka-Schaub, G.E., and Pieters, R. 2003. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood. 102:4541-4546.
9. Muller, H.J., et al. 2000. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br. J. Haematol. 110:379-384.
10. Zalewska-Szewczyk, B., et al. 2007. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk. Lymphoma. 48:931-936.
11. Avramis, V.I., and Panosyan, E.H. 2005. Pharmacokinetic/ pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin. Pharmacokinet. 44:367-393.
12. Muller, H.J., et al. 2001. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br. J. Haematol. 114:794-799.
13. Hak, L.J., et al. 2004. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia. 18:1072-1077.
14. Stams, W.A., et al. 2003. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 101:2743-2747.
15. Appel, I.M., et al. 2006. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 107:4244-4249.
16. Fine, B.M., Kaspers, G.J., Ho, M., Loonen, A.H., and Boxer, L.M. 2005. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res. 65:291-299.
17. Iwamoto, S., Mihara, K., Downing, J.R., Pui, C.H., and Campana, D. 2007. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 117:1049-1057.
18. Pinheiro, J.P., and Boos, J. 2004. The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined? Br. J. Haematol. 125:117-127.
19. Asselin, B.L. 1999. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv. Exp. Med. Biol. 457:621-629.
20. Strefford, J.C., et al. 2006. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc. Natl. Acad. Sci. U. S. A. 103:8167-8172.
21. Watts, C., Matthews, S.P., Mazzeo, D., Manoury, B., and Moss, C.X. 2005. Asparaginyl endopeptidase: case history of a class II MHC compartment protease. Immunol. Rev. 207:218-228.
22. Antoniou, A.N., Blackwood, S.L., Mazzeo, D., and Watts, C. 2000. Control of antigen presentation by a single protease cleavage site. Immunity. 12:391-398.
23. Loak, K., et al. 2003. Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase. Biol. Chem. 384:1239- 1246.
24. Buttle, D.J., Murata, M., Knight, C.G., and Barrett, A.J. 1992. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch. Biochem. Biophys. 299:377-380.
25. van Delft, F.W., et al. 2005. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br. J. Haematol. 130:26-35.
26. Chen, J.M., et al. 1997. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J. Biol. Chem. 272:8090-8098.
27. van Zelm, M.C., et al. 2005. Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J. Immunol. 175:5912-5922.
28. Werner, A., Rohm, K.H., and Muller, H.J. 2005. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. Biol. Chem. 386:535-540.
29. Manoury, B., et al. 1998. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature. 396:695-699.
30. Swain, A.L., Jaskolski, M., Housset, D., Rao, J.K., and Wlodawer, A. 1993. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 90:1474-1478.
31. Aung, H.P., Bocola, M., Schleper, S., and Rohm, K.H. 2000. Dynamics of a mobile loop at the active site of Escherichia coli asparaginase. Biochim. Biophys. Acta. 1481:349-359.
32. Offman, M.N., Tournier, A.L., and Bates, P.A. 2008. Alternating evolutionary pressure in a genetic algorithm facilitates protein model selection. BMC Struct. Biol. 8:34.
33. Porter, C.T., Bartlett, G.J., and Thornton, J.M. 2004. The Catalytic Site Atlas: a resource of catalytic sites and residues identified in enzymes using structural data. Nucleic Acids Res. 32:D129-133.
34. Sexton, K.B., Witte, M.D., Blum, G., and Bogyo, M. 2007. Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain. Bioorg. Med. Chem. Lett. 17:649-653.
35. Li, D.N., Matthews, S.P., Antoniou, A.N., Mazzeo, D., and Watts, C. 2003. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J. Biol. Chem. 278:38980-38990.
36. Jevnikar, Z., and Kos, J. 2008. CTSB (cathepsin B). Atlas Genet. Cytogenet. Oncol. Haematol. http://Atlas GeneticsOncology.org/Genes/ CTSBID40202ch8p23. html.
37. Guo, M., Mathieu, P.A., Linebaugh, B., Sloane, B.F., and Reiners, J.J., Jr. 2002. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B. J. Biol. Chem. 277:14829-14837.
38. Wu, W., et al. 2006. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 66:970-980.
39. Pui, C.H., Robison, L.L., and Look, A.T. 2008. Acute lymphoblastic leukaemia. Lancet. 371:1030-1043.
40. Mitchell, C.D., et al. 2005. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br. J. Haematol. 129:734-745.
41. Vora, A., et al. 2006. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 368:1339-1348.
42. Berman, H.M., et al. 2000. The Protein Data Bank. Nucleic Acids Res. 28:235-242.
43. Case, D.A., et al. 2006. AMBER 9. San Francisco: University of California. http://ambermd.org/ doc9/amber9.pdf.
44. Rizzari, C., et al. 2006. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 91:24-31.